IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes.
Image Credit: Kateryna Kon/Shutterstock.com
As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
TREM-1, an immunoreceptor expressed on innate immune cells, has been identified by Inotrem as a key therapeutic target for many acute or chronic inflammation syndromes, including sepsis and myocardial infarction.
Under the terms of the collaboration, Inotrem will have access to IONTAS’ proprietary Mammalian Display platform, enabling specific high-affinity antibodies with optimal biophysical properties to be selected, to support the Company in developing TREM-1 inhibition-based therapies more efficiently, with reduced Chemistry, Manufacturing and Control (CMC) risk.
IONTAS’ Mammalian Display technology facilitates an increase in the probability and speed of antibodies successfully progressing into cell line development and manufacture. The platform screens antibodies in IgG format, in the context of a mammalian cell, allowing researchers to assess lead candidate function, expression, and developability early in the discovery process.
In addition, large numbers of clones can be screened using fluorescence-activated cell sorting (FACS), in comparison to a low-throughput ELISA.
By harnessing our expertise and novel Mammalian Display technology, we are pleased to support Inotrem in its mission to leverage the therapeutic potential of the TREM-1 pathway. As well as generating an abundance of therapeutic antibody leads, our platform addresses developability issues early, to provide Inotrem with an increased likelihood of successfully identifying and progressing leads.”
Dr. Neil Butt, Chief Business Officer, IONTAS
Dr. Marc Derive, Co-Founder and Chief Scientific Officer of Inotrem, commented: “Following the expansion of our Series B fundraising to €58million, this collaboration with IONTAS allows us to diversify our lead generation process, ultimately helping us to bring new therapies for major public inflammatory diseases.”
For further information, please visit: https://www.iontas.co.uk/technologies/